Last reviewed · How we verify
Lomecel-B medicinal signaling cells
Lomecel-B medicinal signaling cells is a Biologic drug developed by Longeveron Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | Lomecel-B medicinal signaling cells |
|---|---|
| Sponsor | Longeveron Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial. (PHASE2)
- Lomecel-B Effects on Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lomecel-B medicinal signaling cells CI brief — competitive landscape report
- Lomecel-B medicinal signaling cells updates RSS · CI watch RSS
- Longeveron Inc. portfolio CI
Frequently asked questions about Lomecel-B medicinal signaling cells
What is Lomecel-B medicinal signaling cells?
Lomecel-B medicinal signaling cells is a Biologic drug developed by Longeveron Inc..
Who makes Lomecel-B medicinal signaling cells?
Lomecel-B medicinal signaling cells is developed by Longeveron Inc. (see full Longeveron Inc. pipeline at /company/longeveron-inc).
What development phase is Lomecel-B medicinal signaling cells in?
Lomecel-B medicinal signaling cells is in Phase 2.
Related
- Manufacturer: Longeveron Inc. — full pipeline